Yao Yuntao, Liu Yifan, Lu Bingnan, Ji Guo, Wang Lei, Dong Keqin, Zhao Zihui, Lyu Donghao, Wei Maodong, Tu Siqi, Lyu Xukun, Li Yuanan, Huang Runzhi, Zhou Wang, Xu Guofeng, Pan Xiuwu, Cui Xingang
Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Department of Pathology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Cell Oncol (Dordr). 2024 Dec 23. doi: 10.1007/s13402-024-01030-9.
Renal cell carcinoma (RCC), exhibiting remarkable heterogeneity, can be highly infiltrated by regulatory T cells (Tregs). However, the relationship between Treg and the heterogeneity of RCC remains to be explored.
We acquired single-cell RNA-seq profiles and 537 bulk RNA-seq profiles of TCGA-KIRC cohort. Through clustering, monocle2 pseudotime and prognostic analyses, we identified Treg states-related prognostic genes (TSRPGs), then constructing the RCC Treg states-related prognostic classification (RCC-TSC). We also explored its prognostic significance and multi-omics landmarks. Additionally, we utilized correlation analysis to establish regulatory networks, and predicted candidate inhibitors. More importantly, in Xinhua cohort of 370 patients with kidney neoplasm, we used immunohistochemical (IHC) staining for classification, then employing statistical analyses including Chi-square tests and multivariate Cox proportional hazards regression analysis to explore its clinical relevance.
We defined 44 TSRPGs in four different monocle states, and identified high immune infiltration RCC (HIRC, LAG3+, Mki67+) as the highly exhausted subtype with the worst prognosis in RCC-TSC (p < 0.001). BATF-LAG3-immune cells axis might be its underlying metastasis-related mechanism. Immunotherapy and inhibitors including sunitinib potentially conferred best therapeutic effects for HIRC. Furthermore, we successfully validated HIRC subtype as an independent prognostic factor within the Xinhua cohort (OS, HR = 16.68, 95% CI = 1.88-148.1, p = 0.011; PFS, HR = 4.43, 95% CI = 1.55-12.6, p = 0.005).
Through integrated bioinformatics analysis and a large-sample retrospective clinical study, we successfully established RCC-TSC and a diagnostic kit, which could stratify RCC patients with different prognosis and to guide personalized treatment.
肾细胞癌(RCC)具有显著的异质性,可被调节性T细胞(Tregs)高度浸润。然而,Treg与RCC异质性之间的关系仍有待探索。
我们获取了TCGA-KIRC队列的单细胞RNA测序图谱和537份批量RNA测序图谱。通过聚类、monocle2伪时间和预后分析,我们鉴定了Treg状态相关的预后基因(TSRPGs),然后构建了RCC Treg状态相关的预后分类(RCC-TSC)。我们还探讨了其预后意义和多组学特征。此外,我们利用相关性分析建立调控网络,并预测候选抑制剂。更重要的是,在370例肾肿瘤患者的新华队列中,我们使用免疫组织化学(IHC)染色进行分类,然后采用包括卡方检验和多变量Cox比例风险回归分析在内的统计分析来探讨其临床相关性。
我们在四种不同的monocle状态中定义了44个TSRPGs,并确定高免疫浸润性RCC(HIRC,LAG3+,Mki67+)是RCC-TSC中预后最差的高度耗竭亚型(p<0.001)。BATF-LAG3-免疫细胞轴可能是其潜在的转移相关机制。免疫疗法和包括舒尼替尼在内的抑制剂可能对HIRC具有最佳治疗效果。此外,我们在新华队列中成功验证了HIRC亚型是一个独立的预后因素(总生存期,HR = 16.68,95%CI = 1.88 - 148.1,p = 0.011;无进展生存期,HR = 4.43,95%CI = 1.55 - 12.6,p = 0.005)。
通过综合生物信息学分析和大样本回顾性临床研究,我们成功建立了RCC-TSC和一种诊断试剂盒,其可对具有不同预后的RCC患者进行分层并指导个性化治疗。